The enduring material is jointly provided by William Beaumont Hospital, American Academy of CME, Inc., and the American Conference for the Treatment of HIV (ACTHIV).
The 10th Annual American Conference for the Treatment of HIV (ACTHIV) was held April 28-30, 2016 in Dallas, TX. The Conference was supported by funding from the Clinical Education Initiative, New York State Department of Health, AIDS Institute; and from the HIV Medicine Association (HIVMA). The conference and this web archive were supported by educational grants from Bristol-Myers Squibb; Gilead Sciences; Janssen Therapeutics, Division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare.
ONLINE CE CREDIT:
Joel Gallant, MD, MPH, is the Medical Director of Specialty Services at the Southwest CARE Center in Santa Fe, New Mexico. He is Adjunct Professor of Medicine in the Division of Infectious Diseases at the Johns Hopkins University School of Medicine in Baltimore, and Clinical Professor of Medicine at the University of New Mexico School of Medicine.
Estimated time to complete: 30 minutes
Physicians (both specialists and primary care/family medicine), nurse practitioners, and nurses who are frontline providers of care to persons at risk of or with HIV infection. Physician assistants, pharmacists, case managers and other healthcare professionals may also participate.
As a result of participating in this activity, participants should be better able to:
- List the reasons to consider switching therapy in virologically suppressed patient according to latest DHHS guidelines
- Review the results of recent "switch" trials
- Identify the risks of switching therapy in a treatment-experienced patient and how to maximize the safety of switching
Joel Gallant, MD, MPH, indicated he has the following relevant financial relationships to disclose: Advisory Boards: Bristol-Myers Squibb, Gilead Sciences, Janssen Therapeutics, Merck & Co., ViiV Healthcare; Grant Recipient / Research Support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen Therapeutics, Merck & Co., Sangamo BioSciences, ViiV Healthcare
For CME information or credit details, contact: firstname.lastname@example.org
For CNE information or credit details, contact: CEservices@academycme.org
- Lee W et. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicr Agents Chemo 2005;49(5):1898-1906.
- Birkus G et al. Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. Antimicr Agents Chemo 2007;51(2):543-550.
- Babusis D, et al. Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. Mol Pharm 2013;10(2):459-66.
- Ruane P, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr 2013; 63:449-5.
- Sax P, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV- 1 therapy: a randomized phase 2 study. JAIDS 2014. 2014 Sep 1;67(1):52-8.
- Mills A, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis 2016;16:43-52
- Pozniack et al. Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr. 2016;15;71:530-7
- Gallant J, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV 2016;3:e158-65.
- Eron JJ, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375:396-407.
- See also posters and abstracts from meetings cited in presentation.
Joel E. Gallant, MD, MpH
Southwest CARE Center